Firibastat in Treatment-resistant Hypertension

Completed · Phase 3 · Has a placebo group

Conditions studied: Hypertension

In brief

This is a double-blind, placebo-controlled, multicenter, efficacy and safety study of firibastat (QGC001) administered po bid over 12 weeks in male and female subjects ≥18 years of age at Screening, with uncontrolled primary HTN. Subjects will be randomized 1:1 to investigational product (IP) and will receive either firibastat (QGC001) or matching placebo on top of their current chronic antihypertensive treatments.

Key facts

Study ID
NCT04277884
Run by
Quantum Genomics SA
People needed
515
Starts
2020-06-25
Expected to finish
2022-09-20
Last updated by the study team
2022-10-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.